Judson, I., van der Graaf, W. T. (2016) Olaratumab - really a breakthrough for soft-tissue sarcomas? NATURE REVIEWS CLINICAL ONCOLOGY, 13 (9). pp. 535-536. ISSN 1759-4774

Full text not available from this repository.

Abstract

In a recent study, the addition of olaratumab to doxorubicin chemotherapy for patients with soft-tissue sarcoma resulted in prolongation of progression-free survival by only 2.5 months, but an overall survival benefit of 11.8 months; the large disparity between these outcomes raises important questions. We discuss these results in relation to those of other trials, and the implications for sarcoma therapy.

Item Type:	Editorial
Authors (ICR Faculty only):	Judson, Ian and van der Graaf, Winette
All Authors:	Judson, I., van der Graaf, W. T.
Additional Information:	ISI Document Delivery No.: DU4HS Times Cited: 0 Cited Reference Count: 8 Judson, Ian van der Graaf, Winette T. 0 NATURE PUBLISHING GROUP NEW YORK NAT REV CLIN ONCOL
Uncontrolled Keywords:	CONTROLLED PHASE-3 TRIAL
Research teams:	ICR divisions > Cancer Therapeutics > Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) ICR divisions > Clinical Studies > Sarcoma Clinical Trials ICR divisions > Clinical Studies > Clinical and Translational Sarcoma
Depositing User:	Barry Jenkins
Date Deposited:	18 Oct 2016 09:05
Last Modified:	18 Oct 2016 09:05
URI:	http://publications.icr.ac.uk/id/eprint/15341

Actions (login required)

View Item